---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000506"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T06:12:42.097998+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech Q4 net revenue up 49% to $26.3M; net loss widens to $1.7M

## Summary
- Q4 net revenue $26.3M (+49% YoY); full year $86.7M (+33% YoY).
- Q4 net loss $1.7M vs $0.3M loss prior year; full year net loss $9.9M vs $4.4M.
- Adjusted EBITDA Q4 $0.9M (vs $0.4M); full year $2.7M (vs $0.1M).
- Sanara Surgical Q4 net income $0.9M; Tissue Health Plus segment loss $2.6M on platform buildout.
- Exclusive license & distribution deal with BMI for OsStic bone void filler; term loan amended for additional borrowings.

## SEC filing metadata
- accession: 0001641172-25-000506
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000164117225000506/0001641172-25-000506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000164117225000506/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000506
- JSON: https://secwatch.observer/filing/0001641172-25-000506.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.